SCHEDULE: RA Capital Cuts VOR BioPharma Stake to 20.9%

RA Capital Management and its affiliates reported a reduction in their beneficial ownership of VOR BioPharma Inc. common stock to 20.9% through recent open market sales.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") filed an Amendment No. 7 to their Schedule 13D for VOR BIOPHARMA INC.
• The Reporting Persons' aggregate beneficial ownership of VOR BIOPHARMA INC. common stock decreased to 1,432,693 shares, representing 20.9% of the outstanding common stock.
• This percentage is based on 6,853,907 shares outstanding as of September 18, 2025, and includes exercisable stock options.
• The reduction in ownership resulted from a series of open market sales by RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund") between October 15, 2025, and October 20, 2025.
• Total shares sold by the Fund and Nexus Fund during this period amounted to 556,048 shares.
• Sale prices ranged from $28.85 to $31.35 per share.
• The Reporting Persons also hold Common Stock Warrants exercisable for up to 1,056,072 shares and Pre-Funded Warrants exercisable for up to 10,000,000 shares, though exercise is limited by a 9.99% beneficial ownership blocker.
• Vested stock options for 6,190 shares are held by Joshua Resnick, and 83 vested options plus 167 options vesting within 60 days are held by Sarah Reed, both for the benefit of RA Capital.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant institutional investor, RA Capital, reducing its stake in VOR BIOPHARMA INC. through open market sales. This action typically signals a less favorable outlook from a major shareholder.

Negatives

• RA Capital Management and its affiliates, a significant institutional investor, reduced their beneficial ownership in VOR BIOPHARMA INC. from a previously higher stake to 20.9%.
• The reduction involved the sale of 556,048 shares through open market transactions between October 15, 2025, and October 20, 2025.
• Significant selling by a major investor can be perceived negatively by the market and may put downward pressure on the stock price.

Future Outlook

The filing does not contain any forward-looking statements or guidance from VOR BIOPHARMA INC. management.

Industry Context

This filing is a routine disclosure of a change in beneficial ownership by a significant institutional investor in a biopharmaceutical company. Such changes are closely watched by the market as they can signal an investor's evolving view on the company's prospects, but this filing does not provide broader industry analysis.

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by a major institutional investor as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Company Management: May need to address investor concerns regarding the significant selling activity by a prominent shareholder.

Key Dates

Recommendation

The significant reduction in beneficial ownership by a major institutional investor like RA Capital, through open market sales of over half a million shares, typically signals a loss of conviction or a strategic reallocation away from the company. This action by a sophisticated investor often precedes or accompanies periods of underperformance, making a 'sell' recommendation prudent for other investors to consider reducing their exposure or exiting their position.

Keywords

VOR BIOPHARMA, RA Capital, Schedule 13D, Beneficial Ownership, Stock Sales, Institutional Investor, Biopharma, Healthcare